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Dual antiplatelet therapy with aspirin plus thienopyridines has become the standard treatment of patients undergoing coronary
stenting. Clopidogrel has mostly replaced the use of ticlopidine due to its more favourable adverse event proﬁle. However, also
the use of clopidogrel is not without side eﬀects. Clopidogrel major adverse events are represented by marrow suppression,
manifesting with aplastic anaemia, thrombocytopenia and neutropenia. When clopidogrel toxicity occurs, there are few and
unsubstantiated alternative treatments and thus, in these cases, medical decisions may be very diﬃcult. We report a case of
clopidogrel-induced bone marrow toxicity manifesting with severe neutropenia in a patient treated with multiple coronary stents
and provide suggestions for an alternative treatment.
1.Introduction
Dual antiplatelet therapy with aspirin plus clopidogrel has
become the standard treatment of patients undergoing coro-
nary stenting [1, 2]. Clopidogrel exerts its antiplatelet eﬀect
byinhibitingthebindingofadenosine diphosphate(ADP)to
its receptor (P2Y12) and consequent ADP-mediated platelet
activation [3]. Current guidelines of the European Society of
Cardiology suggest starting clopidogrel therapy before any
percutaneous coronary intervention (PCI) or when acute
coronary syndrome (ACS) occurs [4]. Clopidogrel use is
associated with an increased risk of bleeding and may cause
haematological adverse eﬀects,such asthrombotic thrombo-
cytopenicpurpura, haemolytic uremic syndrome, and bone-
marrow suppression, manifesting with aplastic anaemia,
thrombocytopenia [5], and neutropenia [6, 7]. Minor side
eﬀects are represented by diarrhea, vomiting, hepatocel-
lular injury, and skin rash [8–10]. It must be stressed
that all these side eﬀects occur a very low rate [4, 11]. The
CAPRIE trial, which included 9.599 patients treated with
clopidogrel,showedalowannualincidence(0.05%)ofsevere
neutropenia, considered as neutrophil count below 0.45 ×
109/L[4].Nevertheless,itisthoughtthattheactualincidence
of clopidogrel myelotoxicity could be somewhat underesti-
mated [7].
When clopidogrel toxicity occurs, little is known about
the eﬃcacy and safety of alternative treatments, and thus, in
these cases, medical decisions may be very diﬃcult.
We report a case of clopidogrel-induced bone-marrow
toxicity manifesting with severe neutropenia in a patient
treated with multiple coronary stents and provide sugges-
tions for an alternative treatment.
2.Case Report
A 65-year old Caucasian male was admitted to the Depart-
ment of Internal Medicine of our Hospital for the sudden
onset of palpable purpura on lower extremities. The patient
was free from previous cardiovascular events, with untreated
hypertension and smoker status as risk factors. He had no
allergic history and denied any animal bite and recent inges-
tions of new drugs or diet components.2 International Journal of Vascular Medicine
Allhaematological,microbiological,immunological,and
allergic tests were normal. Skin biopsy revealed leukocyto-
clastic vasculitis; therefore, oral steroid therapy was initiated.
The patient remained free from angina and dyspnoea;
nevertheless, the ECG showed ischemic alterations in the
lateral leads, and an echocardiogram showed hypokinesis of
the septal, lateral, and anterior wall. Cardiac enzymes were
within the normal range. Coronary angiogram, performed
after administration of aspirin (100mg) and of a 300mg
loading dose of clopidogrel, showed a critical stenosis of
the left anterior descending artery involving the origin of
the ﬁrst diagonal branch and a severe short stenosis of a
large, dominant circumﬂex artery at the level of the ﬁrst
marginal branch. Percutaneous coronary intervention (PCI)
was then undertaken, which, due to the complex nature of
thestenosis,requiredimplantationoftwodrug-elutingstents
( D E S s )( X i e n c eV ,A b b o t ,T e m e c u l a ,C a l i f ,U S A )o nb o t h
bifurcations. A total of 45mm of everolimus-eluting stent
was used.
After the procedure, clopidogrel (75mg/day) and aspirin
(100mg/day) were prescribed as chronic treatment. Five
weeks later, the patient came backto our Emergency Depart-
ment complaining of fever and dyspnoea. Blood tests re-
vealed severe leukopenia (white cells 1 × 103/µL) with
marked neutropenia (neutrophils 3%), anaemia (haemo-
globin 9.9g/dL), and an important rise in inﬂammatory
markers (C-reactive protein 122mg/dL). A chest computed
tomography revealed multiple inﬂammatory inﬁltrates.
Cytological evaluation of bone-marrow aspirate showed hy-
poplasia of the granulocytic series with blocked matura-
tion to the stage of promyelocytes. Clopidogrel-induced
neutropenia was suspected, and therapy was immediately
discontinued. Application of the Naranjo Causality Scale
classiﬁed theadverse drug reaction as probable[11]. Empiric
antibiotic therapy with levoﬂoxacin (500mg twice daily) was
started and continued for one week. Granulocyte colony-
stimulating factor (G-CSF) (5–10µ/Kg/die) was adminis-
tered for 72 hours. In the following ten days, total leucocytes
and neutrophils count increased and returned within the
normal range.
In consideration of the perceived high risk of stent
thrombosis, it was necessary to replace clopidogrel with an-
other drug in order to ensure adequate platelet inhibition.
Intravenousinfusionofeptiﬁbatide(2µg/kg/min)wasadded
to aspirin [12]. Moreover, anticoagulation was started,
initially with enoxaparin (100UI/Kg twice daily) and then
with oral anticoagulants (dicumarol, titrated to obtain
an International Normalised Ratio of 2-3). A week later,
eptiﬁbatideinfusionwas discontinued, andcilostazol 100mg
twice daily was started. Cilostazol is an antiplatelet that
selectively inhibits cyclic nucleotide phosphodiesterase type
3 (PDE III) [13] and is commonly used for the management
of the peripheral arterial disease. In the following days, the
clinical conditions of the patient progressively improved.
Neutrophil count remained within normal range, and the
patient was discharged after six days. One year after the
start of the combination therapy with aspirin, cilostazol, and
oral anticoagulants, our patient remained asymptomatic.
Repeat angiogram was performed, which showed absence of
restenosis or plaqueprogression. Additionally, optical coher-
ence tomography (OCT) showed complete neointimal cov-
erage of the four implanted stents [14]( Figure 1). Cilostazol
was thus stopped. Three months after cilostazol withdrawal,
the patient is still in good health.
3.Discussion
Severe neutropenia has been reported as a rare adverse eﬀect
of thienopyridines, usually occurring from four weeks to
threemonthsafterthestartoftherapy[3].Neutropeniaisless
frequent with clopidogrel than with ticlopidine, as the latter
directly inhibits colony-forming unit (CFU-C)replication in
the bone marrow in a dose-dependent manner [15]. In our
patient, clopidogrel was considered the most likely causative
agent responsible for this severe haematological injury, as
after fewdaysfrom itswithdrawal andafteronlythreedaysof
G-CSF therapy, neutrophil count rose and remained within
the normal range for the following months [11].
Having to choose a new antiplatelet drug, we excluded
the potential usage of another P2Y12 inhibitor due to the
inherent risk of hematologic toxicity linked to drugs belong-
ing to the same family. Ticlopidine was felt to be unsuitable
for our patient due the well-known risk of bone-marrow
complications reported for this drug [3, 16], and we also
excludedthe newly introduced P2Y12 inhibitor prasugrel for
a possible cross-reaction. At the moment of the event, the
nonthienopyridine ticagrelor had not been tested in large
studies. Thus, we selected cilostazol.
Our choice was inﬂuenced by the favourable pharmaco-
dynamic characteristics of the drug. Cilostazol is a PDEIII
isozyme selective inhibitor which potently inhibits the activ-
ities of PDEIIIA, the cardiovascular PDEIII subtype, thus
increasing the cyclic AMP (cAMP) content of human plate-
lets. Additionally, cilostazol has another important phar-
macological property: the blockage of platelet adenosine
uptake. Intracellular cAMP is degraded via several PDE
and synthesized by adenylate cyclase (AC). AC activity in
turn is controlled by stimulatory (Gs) and inhibitory (Gi)
G-proteins. Adenosine, either from cellular metabolism or
extracellularsources, activatesGsviaA2-receptorsand Givia
A1-receptors. Plateletsand vascularcellsthaton theirsurface
expose A2-receptors, thus, after inhibition of adenosine
uptake, increase their cAMP cytoplasmatic levels. Therefore,
cilostazol increases cAMP levels in platelets thanks to both
PDE inhibition and blockage of adenosine uptake [13].
The most commonly reported side eﬀects for cilostazol
in clinical trials are those related to the vasodilator eﬀect of
the drug, namely, headache (primarily responsible for the
suspension of the treatment) dizziness, and peripheral
edema. Gastrointestinal symptoms such as diarrhea are also
common. Cardiovascular adverse events consist of palpita-
tions, arrhythmias, and ventricular extrasystoles [17]. One
hundred mg twice daily is the recommended dose.
In 2007, Sch¨ afer et al. reported the occurrence of severe
neutropenia under clopidogrel treatment three weeks after
coronary stenting in a 65-year-old woman [18]. Since this
patient was considered at very high risk of stent thrombosis,International Journal of Vascular Medicine 3
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Figure 1: Upper panel shows the left coronary angiogram in the standard right anterior oblique cranial view. (a) At baseline, anterior
descending artery (LAD) demonstrates a critical stenosis involving the origin of the ﬁrst diagonal branch. (b) After two stents implantation
ina“tandsmallprotrusion”(TAP)fashion,goodangiographicresultcanbe seen.(c)Oneyearangiographicfollowupatteststhatgoodresult
ismaintained.(d)opticalcoherencetomography(OCT)analysisofLADanddiagonalbranch(4representative slices)atoneyearshowsgood
neointimalcoverageofthe stentstruts,without“malapposition”.Lowerpanelshowstheleftcoronaryangiograminthestandardleftanterior
oblique view. (e) At baseline, critical stenosis of the circumﬂex artery (LCX) at the level of the ﬁrst marginal branch is visible. (f) After two
stentsimplantationina“culotte”fashion,goodangiographicresultcanbeseen.(g)Oneyearangiographicfollowuptestiﬁesthemaintenance
of good angiographic result. (h) optical coherence tomography (OCT) analysis of LAD and diagonal branch (4 representative slices) at one
year shows good neointimal coverage of the stent struts, without “malapposition”.
association treatment with aspirin (150mg/d) and dipyri-
damole (200mg/bid) was started. Also, oral anticoagulant
therapy was added, because impaired left ventricular func-
tion was present [19]. Available followup, however, was only
two months.
In our case, similar to Sch¨ afer’s team, we opted for anti-
coagulation [18, 19], since left ventricular function was re-
duced; nevertheless, we introduced cilostazol instead of di-
pyridamole.
Our preference of cilostazol was conditioned by two fac-
tors: (1) cilostazol inhibits platelets more eﬀectively because
its action involves with two mechanisms (PDE inhibition
and blockage of adenosine uptake); (2) on clinical grounds,
dipyridamole has never been tested as a part of antiplatelet
therapy after PCI with DES,whereas cilostazol has beenused
in several studies.
A large meta-analysis published in 2008 reviewed 23
randomized clinical trials (RCTs) for a total of 5428 patients.
Coprimary end points were angiographic restenosis and
repeat revascularization. Results showed the eﬀectiveness of
cilostazol in reducing restenosis rate and repeat revascu-
larization after PCI with DES; furthermore, cilostazol also
appeared to be safe, with no signiﬁcant increase in the risk
of stent thrombosis or bleeding [20].
Cilostazol has been tested as addition to the usual dual
antiplatelet therapy (DA) to reduce the risk of stent throm-
bosis. A Korean study (2009) investigated the eﬀectiveness
of the triple antiplatelet therapy (TA) (aspirin, clopidogrel,
plus cilostazol) in diabetic patients undergoing coronary
stent. 55 type II diabetic patients DES-treated were stratiﬁed
to receive DA (n = 34) and TA (n = 21). Platelet aggregation
was studied with adenosine diphosphate (ADP) stimulation,
and then, the antiplatelet power was compared using light
transmittance aggregometrybetweengroups.Resultsshowed
that TA was more potentthan the DA.These ﬁndings suggest
that TA may be more eﬀective in preventing thrombotic
complications after DES implantation in type 2 diabetic
patients [21]. Similar conclusions, regardless of diabetes,
arise from Tamhane’s meta-analysis that analyzed 10 RCTs
(n = 2,809 patients) comparing TA with standard DA:
antiplatelet therapy with cilostazol was associated with a sig-
niﬁcant reduction in angiographic restenosis [22]. Another
meta-analysis, including 1457 post-PCI patients, studied not
only the angiographic restenosis rate, but also the frequency
of major adverse cardiac and/or cerebrovascular events
(MACE/MACCE), stent thrombosis and bleeding in TA
versus DA, after a median follow-up period of 6–9 months.
Coprimary endpointswerenotonlyangiographicrestenosis,4 International Journal of Vascular Medicine
but also the rates of major adverse cardiac and/or cere-
brovascular events (MACE/MACCE), stent thrombosis, and
bleeding in TA versus DA. This careful analysis showed that
cilostazol was eﬀective in reducing angiographic restenosis
without any signiﬁcant beneﬁt for MACE/MACCE rates
[23].TheCILTON-Ttrial(960DES-treatedpatientsenrolled
and randomized to receive DA or TA) shows more dis-
appointing results: despite the greater reduction of platelet
reactivity by addition of cilostazol to conventional DA
therapy, TA did not show superiority in reducing cardiac
death, nonfatal myocardial infarction, ischemic stroke, and
target lesion revascularization [24]. However, TA appeared
to have a beneﬁcial clinical eﬀect in an higher-risk popu-
lation (patients with acute ST-segment elevation myocardial
infarction (STEMI) undergoing PCI). A total of 4203
STEMI treated by DES were analyzed retrospectively. They
received either DA (n = 2569) or TA (n = 1634). MACE
after 8 months were signiﬁcantly lower in the group with TA
[25].
Of note, other studies tested the eﬀectiveness and the
safety of cilostazol as a substitute for clopidogrel in associ-
ation with aspirin (the drug combination we used in our
patient). A study on 280 patients showed that combination
therapy with aspirin and cilostazol for the prevention of
stent thrombosis (after only 1 month of aspirin, cilostazol,
and clopidogrel combination treatment) was comparable
or superior to aspirin and clopidogrel in diabetic patients
undergoing DES implantation [26]. In particular, the risk
of late stent thrombosis, in this complex population with
high baseline risk, was not increased. In a larger population
(689 patients), another team also obtained the same results
although the patients were all treated with BMS [27]. More
recently, a large, randomised Korean study in 1315 DES-
treated patients proved the eﬃcacy of cilostazol in the
preventionofstent thrombosis. During theinitial six months
after PCI, patients were randomized to TA or DA (aspirin +
clopidogrel); then, after this ﬁrst period, all patients were
randomized to DA with aspirin and cilostazol or DA with
aspirin and clopidogrel [28]. Results were encouraging for
cilostazol both in TA (association) and in DA (alternative)
for the prevention of stent thrombosis.
As our strategy led to a successful long-term outcome for
ad i ﬃcult patient, we speculate that cilostazol might con-
stitute an acceptable alternative treatment when thienopy-
ridines are absolutely contraindicated, such as in cases of
bone marrow toxicity.Further large-scale, randomized trials,
however, are needed to fully elucidate this topic.
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